This story was originally published on PharmaVoice. To receive daily news and insights, subscribe to our free daily PharmaVoice newsletter. When Madrigal Pharmaceuticals secured its history-making ...

In November 2025, Madrigal Pharmaceuticals announced positive two-year results from the open-label compensated MASH cirrhosis arm of its Phase 3 MAESTRO-NAFLD-1 trial, showing statistically ...

MONSTA X is back with new music! On November 14 at 2 p.m. KST, MONSTA X released their new digital single “baby blue” along with the music video. “baby blue” is an electronic pop track that captures ...

Madrigal (shoulder) cleared waivers and opted for free agency Thursday. Madrigal missed the full 2025 campaign after undergoing surgery in February to repair a fractured left shoulder. The infielder, ...

Madrigal Pharmaceuticals' Rezdiffra generated sales of $287 million in the third quarter for a 35% sequential jump from Q2. In just its fifth full quarter on the market, the world’s first treatment ...

Madrigal Pharmaceuticals is reiterated as a Strong Buy, driven by Rezdiffra's rapid US launch and recent European approval. Q2 2025 saw Rezdiffra sales reach $213M and >23,000 patients, with Q3 ...

Why are we asking for donations? Why are we asking for donations? This site is free thanks to our community of supporters. Voluntary donations from readers like you keep our news accessible for ...

Join Post Sports+ for exciting subscriber-only features, including real-time texting with Greg Joyce about the inside buzz on the Yankees. Camilo Doval was brought in by the Yankees as a former closer ...

The New York Yankees' bullpen got much, much better on Thursday. New York focused most of its efforts on position players in the week leading up to the deadline, but went bananas on the relief ...

July 30 (Reuters) - U.S. drugmaker Madrigal Pharmaceuticals (MDGL.O), opens new tab has struck a licensing deal with CSPC Pharmaceutical Group (1093.HK), opens new tab that could be worth more than $2 ...

Madrigal Pharmaceuticals is paying $120 million upfront for a preclinical GLP-1 receptor agonist that the biopharma plans to pair up with its approved fatty liver disease med Rezdiffra. The GLP-1 drug ...